Abstract
Dysfunction of the mucosal immune system plays an important role in inflammatory bowel disease (IBD) pathogenesis. Dendritic cells are emerging as central players based on both our increasing understanding of how genetic susceptibility impacts the mucosal immune system and the key role of dendritic cells in regulating response to gut microflora. We discuss areas of therapeutic opportunity in this evolving landscape.
Keywords:
Crohn's disease; colitis; dendritic cell; inflammation; inflammatory bowel disease; mucosal immunity.
© 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / therapeutic use*
-
Colitis, Ulcerative / drug therapy*
-
Colitis, Ulcerative / genetics
-
Colitis, Ulcerative / immunology
-
Colitis, Ulcerative / microbiology
-
Colitis, Ulcerative / pathology
-
Crohn Disease / drug therapy*
-
Crohn Disease / genetics
-
Crohn Disease / immunology
-
Crohn Disease / microbiology
-
Crohn Disease / pathology
-
Dendritic Cells / drug effects*
-
Dendritic Cells / immunology
-
Drug Discovery*
-
Gastrointestinal Agents / therapeutic use*
-
Humans
-
Immunity, Mucosal / drug effects*
-
Intestines / drug effects*
-
Intestines / immunology
-
Intestines / microbiology
-
Intestines / pathology
-
Mice
-
Molecular Targeted Therapy
Substances
-
Anti-Inflammatory Agents
-
Gastrointestinal Agents